Litigation Details for Hospira Inc. v. Actavis LLC (D. Del. 2014)

Hospira Inc. v. Actavis LLC (D. Del. 2014)

Docket	1:14-cv-00488	Date Filed	2014-04-18
Court	District Court, D. Delaware	Date Terminated	2015-05-28
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,716,867
Link to Docket	External link to docket

Details for Hospira Inc. v. Actavis LLC (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-18				External link to document

Litigation summary and analysis for: Hospira Inc. v. Actavis LLC (D. Del. 2014)

Last updated: April 26, 2026

Hospira Inc. v. Actavis LLC (D. Del. 1:14-cv-00488): What the litigation covers, what matters, and what it means

What case is this and what patents were at issue?

Hospira Inc. sued Actavis LLC (and related parties) in the District of Delaware in case No. 1:14-cv-00488. The dispute is tied to the ANDA regulatory pathway for a Hospira injectable product and pivots on whether Actavis could launch a generic during the life of Hospira’s listed patents under the Hatch-Waxman framework.

The case’s practical focus is the standard Hatch-Waxman claim set: patent invalidity, non-infringement, and infringement, as framed by the ANDA submission and the asserted Orange Book patents.

What is the litigation posture and key procedural timeline?

The record for this case is procedural and claim-driven, consistent with ANDA patent litigation practice in Delaware. The litigation progresses through the customary phases:

• Pleading of infringement and defenses tied to the ANDA product and the asserted patent claims.
• Markman and claim construction (typically decisive in Delaware ANDA cases).
• Summary judgment and/or trial on infringement/invalidity, depending on the scope of disputed issues.
• Claim-by-claim disposition that determines whether Actavis could proceed with launch at risk.

What were the legal issues in play (Hatch-Waxman mechanics)?

The litigation turns on three recurring legal question types:

1) Infringement vs. ANDA product design

• Whether Actavis’s ANDA product meets every limitation of the asserted claims.
• How claim construction affects element-by-element comparison.

2) Invalidity

• Anticipation, obviousness, written description, enablement, and other §102/§103 and §112 theories as invoked in ANDA practice.

3) Regulatory “safe harbor” and timing

• Whether any alleged infringement falls within Hatch-Waxman’s carve-outs for certain activities connected to regulatory approval.
• Whether the court’s decision determines whether Actavis is blocked from launch until patent expiry or licensing.

Why this case matters commercially

This matter affects:

• Launch timing (delay vs. at-risk entry).
• Market access to the relevant injectable drug.
• Pricing and supply dynamics for the branded product and first wave generic entrants.

The business impact typically concentrates on whether the court enforces an injunction based on a finding of infringement not cured by invalidity.

---

How to read the outcome: what a Delaware ANDA decision usually turns on

Even without reproducing the full merits text here, the business logic of a Delaware ANDA case is stable:

What does a “non-infringement” finding imply?

A non-infringement disposition typically means Actavis can proceed because the ANDA product does not fall within the asserted patent claim scope as construed by the court.

What does an “invalidity” finding imply?

An invalidity finding clears the asserted patent barrier regardless of the ANDA product design, because the claim(s) can no longer be enforced against the market entry.

What does an “infringement” finding imply?

An infringement ruling, if not offset by invalidity, typically supports an injunction and delays entry. It can also shift the negotiation posture for a license or redesign around non-infringing claim scope.

---

Litigation analysis: the strategic levers in Hospira vs. Actavis

What do both sides generally optimize for in these cases?

Hospira’s litigation posture usually seeks:

• Strong claim construction that reads onto the ANDA product.
• Narrowing of permissible generic design choices.
• Win on at least one asserted patent that triggers blocking relief.

Actavis’s litigation posture usually seeks:

• A claim construction that narrows claim reach.
• Invalidity based on prior art or claim disclosure defects.
• A non-infringement narrative anchored to ANDA composition, process, or performance properties, depending on the asserted claims.

What tends to decide outcomes in Delaware ANDA disputes?

• Construction of key claim terms tied to formulation/process/performance.
• Scientific record for whether the generic matches Hospira’s claimed parameters.
• Prior-art mapping quality for anticipation/obviousness.
• Written description and enablement where the claims cover broad ranges or functional language.

---

Key business implications by scenario

If the court blocked launch

• Actavis likely faced a delayed entry window and potential commercial pressure from branded supply strategy and remaining generics.
• Hospira’s leverage increases for settlement or licensing around the court’s infringement view.

If the court cleared launch

• The market typically sees:
  • faster generic uptake,
  • pressure on branded pricing,
  • and near-term margin compression for Hospira unless it controls through formulary access and contracting.

---

Evidence map (what the record typically contains in cases like this)

A standard Delaware ANDA case record includes:

• ANDA product parameters and manufacturing/process documentation in discovery.
• Expert declarations for claim construction positions and infringement mapping.
• Patent prosecution history and prior-art references for validity arguments.
• Court orders on discovery disputes, Markman, summary judgment, and any injunction-related steps.

For decision-making, investors and strategists should track:

• which patents survive dispositive motions,
• which claim terms are construed narrowly vs broadly,
• and what the final infringement/invalidity outcomes are on each asserted claim set.

---

Key Takeaways

• Hospira Inc. v. Actavis LLC (1:14-cv-00488, D. Del.) is a Hatch-Waxman ANDA patent infringement/invalidity dispute where the court’s claim construction and claim-by-claim merits decide whether Actavis can launch.
• The business outcome in these Delaware cases is typically binary at the margin: launch blocked by enforceable infringement or cleared by non-infringement and/or invalidity of the asserted claims.
• The litigation’s commercial value is tied to injunction risk and timing, which drive entry strategy, settlement posture, and market share planning.

---

FAQs

What is the legal framework behind 1:14-cv-00488?

It is an ANDA-related patent dispute under the Hatch-Waxman framework, where the asserted patents come from the Orange Book listing and the claims are tested against the ANDA product and the patent validity record.

What is usually the most important court step in these cases?

Claim construction (often via Markman), because it controls whether each asserted claim limitation reads on the ANDA product.

Does the final outcome turn on infringement or validity?

Either can be dispositive. Courts can clear launch by finding non-infringement or invalidity on asserted claims.

How does the court decision affect generic launch timing?

If the court finds enforceable infringement on asserted claims that are not invalidated, launch is typically blocked by injunction. If the asserted claims are cleared, launch can proceed.

What commercial metrics should track this case?

Outcome on each asserted patent, the injunction status (if any), and the effect on launch timing for the specific injectable product covered by the ANDA.

---

References

1. Hospira Inc. v. Actavis LLC, No. 1:14-cv-00488 (D. Del.).